Synspira, Inc.   Report issue

For profit Phase 1
Founded: Boston MA United States (2017)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03309358
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Anagram Therapeutics, Inc. | Synspira, Inc.